Avid Bioservices Inc (CDMO)

[biopharm]

Dmitry Gabrilovich : Peregrine Pharmaceuticals KOL :

11.14.2014

IMMUNOBIOLOGY RESEARCH IN PROGRESS
Fall 2014 Schedule

Dmitry Gabrilovich, M.D., Ph.D.
Professor The WistarInstute
Class of ’62 Auditorium, JM

http://www.med.upenn.edu/immun/user_docs/Fall2014Poster.pdf

Well Nov 14th is much too long to wait for Dmitry Gabrilovich to continue his March on with spreading the word of how powerful MDSC's can be in relation to homeostasis and for thee that can control MDSC's, will force Big Pharma into collaboration after collaboration... after collaborations

Bavituximab and PS Targeting looks to be that force that controls MDSC's, which in turn... brings complete stabilization back to homeostasis

Wednesday, October 8, 2014

8:00 am
Registration and Continental Breakfast

Session 5: Therapeutics 8:00 a.m. - 11:00 a.m.
-------------------------------------------------------
9:00 am
Irving L. Weissman, Stanford University School of Medicine, Stanford, CA
Normal and neoplastic stem cells
-------------------------------------------------------
9:30 am
Margaret Shipp, Dana-Farber Cancer Institute, Boston, MA
Genetic basis of immune evasion in lymphoid malignancies
---------------------------------------------------------
10:00 am
Alexander Lesokhin, Memorial Sloan-Kettering Cancer Center, NY
Myeloid derived suppressor cells as a potential biomarker for cancer immunotherapy
-------------------------------------------------------
10:30 am
Dmitry Gabrilovich, The Wistar Institute, Philadelphia, PA
Regulation of myeloid-derived suppressor cells in cancer
---------------------------------------------------------
11:00 am
James Allison, The University of Texas MD Anderson Cancer Center, Houston, TX
Closing comments

https://www.regonline.com/builder/site/tab2.aspx?EventID=1477794

----------------------

Alexander Lesokhin ... maybe we have more believers out there, than just the night nurses of IHUB

I am an oncologist who specializes in treating patients with multiple myeloma and related disorders. I am interested in understanding how cancers such as multiple myeloma are able to evade the immune system. My research focuses on learning how some treatments reverse this process and on developing innovative ways to use the immune system to treat multiple myeloma.

The advent of many new treatments in the past ten years makes this a very exciting time for physicians taking care of patients with multiple myeloma. Our team of myeloma specialists and support staff offers the newest treatments through a broad range of clinical trials to advance the level of care and improve the chance of a good outcome for all of our patients.

http://www.mskcc.org/cancer-care/doctor/alexander-lesokhin

--------------------------------------------------------

Do I hear blood test anyone? Now tell me this, those within the Data Monitoring Committee watching over Peregrines SunRise trial... will they be interested in blood tests ? Will the DMC use "ALL" knowledge there is in its entirety to make decision, to not watch patients remain on Docetaxel, without Bavituximab... if they know that Bavituximab decreases those MDSC's and those MDSC's are a biomarker ??? Hell... we have flipped-PS as the global biomarker of all cancer cells and we have MDSC's coming into biomarker territory. No wonder why all the fuss here lately.

No shirt, No shoes.. no problems

----------------------------------------------------

Novel blood test for predicting response to cancer therapy to be commercialized by Ludwig start-up Serametrix Corporation

Dec 9, 2013 | 4:27 pm

December 9, 2013, New York, NY – Ludwig startup Serametrix Corporation has announced the launch of an important new blood test for cancer patients. The test measures a patient’s level of circulating Myeloid Derived Suppressor Cells (MDSCs) that are known to decrease anti-tumor immunity and are associated with poor survival rates in cancer patients. The service will initially be offered to drug companies engaged in the clinical development of experimental immunotherapies. In the future, the test may also be used as a way for clinician's to monitor the likelihood of recurrence in cancer patients.

The test was developed under the direction of Jedd Wolchok and Alex Lesokhin, Ludwig researchers at Memorial Sloan-Kettering Cancer Center (MSKCC). The license agreement between MSKCC and Serametrix also covers the use of the test in the clinic, for example, to enable physicians to determine whether a cancer patient is a suitable candidate for approved immunotherapy.

The Ludwig researchers recently discovered that patients with low levels of a sub-group of MDSCs were more likely to respond well to ipilimumab, an immunotherapy approved for the treatment of melanoma.

“This novel assay has the potential to become a valuable tool in the clinical development of immune therapy in cancer patients,” said Wolchok, director of the Ludwig Collaborative Laboratory at MSKCC and Chair of the Scientific Advisory Board at Serametrix.

The assay will be offered as a fee-for-service and samples will be analyzed at the Serametrix facility in Carlsbad, California. A separate agreement allows for the co-development of a sample collection and handling strategy to enable scaled-up support of later phase clinical trials.

The new test will be an important addition to an existing suite of assays already offered by Serametrix. Such assays include the NY-ESO-1 serum profiling assay licensed in 2009 from the Ludwig Institute for Cancer Research in New York which part owns Serametrix. “Our serum profiling business has seen strong growth in recent years,” said Henry Hepburne-Scott, Director of Business Development at Serametrix. “This new assay will help us to meet future demands for patient monitoring as the substantial growth of cancer immunomonitoring continues.”

http://www.ludwigcancerresearch.org/news/novel-blood-test-predicting-response-cancer-therapy-be-commercialized-ludwig-start-serametrix

-----------------------------------------------------------

Jedd Wolchok talks about immunotherapy and the foundation work set by William Coley, he mentions James Allison and pay attention to how he did not mention MDSC's in this video and he talks much about Ipilimumab (Yervoy) but one year later after this video >> in Dec 2013 he is working with Alexander Lesokhin on a new blood test for cancer patients, measuring circulating MDSC's

I know this video is devoted much to Yervoy, but Peregrine now has a combo trial with Yervoy+Bavi and with all this new information regarding MDSC's, Jedd Wolchok must be impressed

enjoy the next days or weeks or whatever... all hell is about to break loose